MedTrace Logo

A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)

NCT02371967 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-10-09

No results posted yet for this study

Summary

This prospective, observational, cohort study is designed to assess the effectiveness and safety outcomes of vismodegib and to assess actual day-to-day disease and participant management by the physician.

Conditions

Interventions

DRUG

Vismodegib

Vismodegib therapy will be given in compliance with the physician's standard practice as per local label.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-08
Primary Completion
2020-08-19
Completion
2020-08-19

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02371967 on ClinicalTrials.gov